A new drug for the treatment of HIV infection in adults in the UK is launched today, the drug Juluca is the first 2-drug, single pill available for the treatment of HIV, making it the smallest complete treatment available for people living with the condition.

The drug is available to those who are virologically suppressed (HIV-1 RNA less than 50 copies per mL) and have been on a stable antiretroviral regimen for at least six months without side effects or complications.

Modern treatment and medical advances mean that people living with HIV are healthier and living longer than ever before. However, a life time of treatment exposes them to ongoing side-effects and drug-to-drug interactions which can negatively impact their quality of life.

Clinical trials have shown that Juluca (dolutegravir/rilpivirine) is as effective as the current standard of care and is a potential treatment option to support people living with HIV who are now growing old.

Dolutegravir/rilpivirine is ViiV Healthcare’s first 2-drug regimen, once-daily, single-pill that combines dolutegravir the most widely prescribed integrase inhibitor (INI) worldwide[i], with the non-nucleoside reverse transcriptase inhibitor (NNRTI) rilpivirine.

Watch our video here to see Paida, and George – two individuals who have been living with HIV. We learn about their struggles, and how the new drug has effected them and their loved ones.